Managing drug shortages during a pandemic: tocilizumab and COVID-19

CMAJ. 2021 May 25;193(21):E771-E776. doi: 10.1503/cmaj.210531. Epub 2021 May 5.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antiviral Agents / therapeutic use*
  • COVID-19 / diagnosis
  • COVID-19 / mortality
  • COVID-19 / therapy
  • COVID-19 Drug Treatment*
  • Critical Care / methods
  • Drug Industry / organization & administration*
  • Female
  • Health Care Rationing / methods*
  • Health Care Rationing / organization & administration
  • Health Resources / supply & distribution*
  • Health Services Accessibility / organization & administration*
  • Humans
  • Male
  • Middle Aged
  • Ontario / epidemiology
  • Pandemics
  • Respiration, Artificial
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • tocilizumab